The claim that bearish trader positions in Waldencast (NASDAQ: WALD) have collapsed by 84.6 percentage points cannot be verified through available public data sources. However, the stock’s actual trading metrics tell a more complex story than any simple reversal narrative. As of July 2026, Waldencast trades at $1.68, down 71.03% over the past 52 weeks, with short interest representing just 0.77% of outstanding shares—a relatively modest bearish position by market standards.
The gap between a dramatic position collapse claim and the underlying stock fundamentals suggests investors should scrutinize the sources and timing of such claims carefully before acting. What is measurable about Waldencast’s situation is more sobering than celebratory. The company, which operates the Obagi skincare brand through its majority-owned subsidiary, faces genuine business challenges reflected in flat year-over-year revenue and the strategic sale of its Obagi Japan division for $82.5 million to shore up its debt position. Any meaningful rebound will depend less on trader sentiment shifting and more on whether the company’s core business can generate sustainable growth and profitability.
Table of Contents
- What Does Short Interest Data Actually Show About Waldencast?
- Flat Revenue Growth and the Challenge Facing the Core Business
- The Bridgepoint Acquisition and Strategic Restructuring
- Short Interest Levels and Historical Trading Parallels
- SEC Investigation Closure and Reduced Legal Overhang
- Debt Position and Cash Flow Constraints
- What an Actual Rebound Would Require
What Does Short Interest Data Actually Show About Waldencast?
Short interest on Waldencast sits at 0.77% of outstanding shares, representing approximately 984,965 shares. This figure is notably low compared to heavily-shorted stocks in other sectors, where bearish bets routinely exceed 5-10% of float. In absolute terms, the bearish positioning in WALD is neither dramatic nor particularly crowded. This raises a critical question about the “84.6 percentage points” claim: if genuine, it would suggest short interest collapsed from above 85% of shares to near zero—a scenario that would be accompanied by violent short-covering rallies and would be impossible to miss in trading volume data.
The actual dynamics suggest a different interpretation. The stock’s decline reflects fundamental business weakness rather than a crowded short squeeze waiting to unwind. When a stock falls 71% in 52 weeks while short interest remains modest, the decline is typically driven by sellers responding to deteriorating business prospects, not a reversal of trader sentiment. Waldencast’s low short interest indicates that even bearish traders have limited conviction about further downside, or that the market has already priced in expected bad news.
Flat Revenue Growth and the Challenge Facing the Core Business
Waldencast reported net revenue of $272.1 million for fiscal year 2025, flat compared to the prior year. This stagnation in the top line is the primary issue weighing on the stock, far more than any trader positioning. Q4 2025 revenue of $72.0 million shows no acceleration entering 2026, while adjusted EBITDA of $16.1 million for the full year (or 5.9% margin) demonstrates that even after cost management, the business is generating thin profitability. The Q4 adjusted EBITDA of $6.6 million suggests the company faces seasonal volatility in its earnings power.
Flat revenue in a growth-oriented market is a structural problem. The Obagi brand, while established in professional skincare channels, operates in a highly competitive segment where luxury and mass-market competitors constantly introduce new products and marketing campaigns. Without top-line momentum, the company’s ability to invest in innovation, marketing, and distribution is constrained. This is not a technical trading problem—it is a business momentum problem that a trader positioning shift cannot resolve.
The Bridgepoint Acquisition and Strategic Restructuring
Bridgepoint is acquiring 100% of Obagi Medical Products Company’s equity, with closing expected in Q3 2026. This acquisition fundamentally changes the investment thesis for Waldencast shareholders. Under Bridgepoint’s ownership, Obagi will operate as a private company, removing public market liquidity and quarterly earnings pressure.
For current WALD shareholders, the acquisition represents a potential exit opportunity, though Waldencast trades significantly below what pre-acquisition valuations might suggest. The company’s earlier sale of Obagi Japan for $82.5 million was framed as a strategic move to strengthen its debt position. This asset sale, while generating near-term cash, also permanently reduces the company’s geographic diversification and eliminates a potentially growing market. The combination of these two moves—divesting Japan and preparing for full acquisition—signals that Waldencast’s management and investors view the standalone public company path as unsustainable.
Short Interest Levels and Historical Trading Parallels
A 0.77% short interest level places Waldencast in the category of stocks with minimal bearish positioning. Compare this to situations where dramatic short squeezes occur: GameStop held short interest above 100% of float before its 2021 rally, Tesla sustained 20%+ short interest through multiple rallies, and Nvidia peaked with short interest above 3-4% during its own volatility periods. Waldencast’s current short interest is lower than many healthy, profitable companies simply because there is little conviction—bullish or bearish—around the stock.
When a stock experiences a 71% decline and short interest remains this low, it typically means short-sellers have already exited, longs have capitulated, and trading volume has dried up. This is the opposite of a setup for a dramatic reversal. The lack of a crowded short position also means there is no latent “squeeze” energy to propel the stock higher. Any future recovery in WALD would need to come from improving business fundamentals, not from traders covering bearish bets.
SEC Investigation Closure and Reduced Legal Overhang
The SEC concluded its investigation into Waldencast’s financial restatement and the historical accounting practices at Obagi Cosmeceuticals, determining it does not intend to recommend enforcement action. This represents meaningful good news for the company and removes an important source of uncertainty. Past restatements and SEC scrutiny often create a credibility discount on a stock that persists even after investigations conclude. However, the closure of the SEC investigation is primarily housekeeping—it removes a negative but does not create a positive catalyst.
No enforcement action means the company is not facing additional fines, penalties, or restrictions on its leadership. What it does not do is fix the flat revenue problem or improve the skincare brand’s market position. For investors hoping that this legal clearance signals an operational turnaround, the distinction matters. Regulatory approval to operate is necessary but insufficient for a stock recovery.
Debt Position and Cash Flow Constraints
The company’s decision to sell Obagi Japan for $82.5 million indicates that debt management and cash preservation remain urgent priorities. A healthy, growing company with robust cash flow does not sell profitable divisional assets. This sale provided one-time cash relief but highlighted the ongoing tension between servicing debt and funding business growth.
Waldencast’s adjusted EBITDA of $16.1 million for the full year likely covers debt service, but leaves minimal room for capital expenditure, acquisitions, or share buybacks. Going forward, the company’s ability to invest in new products, marketing campaigns, or digital channels is constrained by its leverage. This structural limitation means Waldencast cannot easily accelerate growth organically, and will instead rely on the Bridgepoint acquisition to provide financial restructuring and operational improvements under private ownership.
What an Actual Rebound Would Require
A genuine recovery in Waldencast would require measurable acceleration in Obagi brand revenue and margin expansion. The most recent data shows no such acceleration—FY2025 revenue was flat and Q4 showed no quarter-over-quarter improvement. For the stock to move higher under Bridgepoint’s ownership, the acquiring firm would need to execute successfully on cost management, product innovation, or market expansion.
These are concrete, observable metrics that would appear in subsequent financial reports. Until then, claims of position collapses or dramatic trader reversals should be treated as speculation unsupported by available public data. The verified metrics—71% stock decline, flat revenue, 0.77% short interest, and an ongoing acquisition—paint a picture of a company managing decline under new ownership, not one staging a convincing rebound.